163 related articles for article (PubMed ID: 31728714)
1. The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants.
Patel M; Chen J; McGrory S; O'Gorman M; Nepal S; Ginman K; Pithavala YK
Invest New Drugs; 2020 Feb; 38(1):131-139. PubMed ID: 31728714
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
Chen J; Xu H; Pawlak S; James LP; Peltz G; Lee K; Ginman K; Bergeron M; Pithavala YK
Adv Ther; 2020 Feb; 37(2):745-758. PubMed ID: 31863284
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants.
Li J; Pithavala YK; Gong J; LaBadie RR; Mfopou JK; Chen J
Clin Pharmacokinet; 2021 Oct; 60(10):1303-1312. PubMed ID: 33937953
[TBL] [Abstract][Full Text] [Related]
4. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
5. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
6. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
Tachibana M; Matsuki S; Maekawa Y; Kuroda K; Shimizu T; Tsutsumi J; Ishizuka H
Clin Transl Sci; 2023 Nov; 16(11):2153-2162. PubMed ID: 37705321
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
8. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
[TBL] [Abstract][Full Text] [Related]
9. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Hibma JE; O'Gorman M; Nepal S; Pawlak S; Ginman K; Pithavala YK
Cancer Chemother Pharmacol; 2022 Jan; 89(1):71-81. PubMed ID: 34698901
[TBL] [Abstract][Full Text] [Related]
11. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults.
Cox DS; Van Eyck L; Pawlak S; Beckerman B; Linn C; Ginman K; Thay Cha Y; LaBadie RR; Shi H; Damle B
Br J Clin Pharmacol; 2023 Sep; 89(9):2867-2876. PubMed ID: 37184075
[TBL] [Abstract][Full Text] [Related]
12. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Tran JQ; Zhang P; Ghosh A; Liu L; Syto M; Wang X; Palmisano M
Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
[TBL] [Abstract][Full Text] [Related]
13. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
[TBL] [Abstract][Full Text] [Related]
16. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
Desch M; Wunderlich G; Goettel M; Goetz S; Liesenfeld KH; Chan TS; Rosenbrock H; Sennewald R; Link J; Keller S; Wind S
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):91-103. PubMed ID: 34716565
[TBL] [Abstract][Full Text] [Related]
17. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
[TBL] [Abstract][Full Text] [Related]
18. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
Dai D; Yang H; Nabhan S; Liu H; Hickman D; Liu G; Zacher J; Vutikullird A; Prakash C; Agresta S; Bowden C; Fan B
Eur J Clin Pharmacol; 2019 Aug; 75(8):1099-1108. PubMed ID: 31011758
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Li J; Kankam M; Trone D; Gammon G
Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
[TBL] [Abstract][Full Text] [Related]
20. Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
Gardin A; Shakeri-Nejad K; Feller A; Huth F; Neelakantham S; Dumitras S
Eur J Clin Pharmacol; 2019 Nov; 75(11):1565-1574. PubMed ID: 31392364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]